Translational Therapeutics
British Journal of Cancer (2007) 96, 445–449. doi:10.1038/sj.bjc.6603596 www.bjcancer.com
Published online 23 January 2007
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
K S M Smalley1, R Contractor1, N K Haass1, J T Lee1, K L Nathanson2,4, C A Medina2, K T Flaherty3,4 and M Herlyn1
- 1The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA
- 2Division of Medical Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
- 3Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
- 4Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA
Correspondence: Dr KSM Smalley, E-mail: ksmalley@wistar.org
Revised 13 December 2006; Accepted 19 December 2006; Published online 23 January 2007.
Abstract
The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
Keywords:
melanoma, Ki67, biomarker, BRAF, MAP kinase, Akt
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Cancer Gene Therapy Original Article
BRAF Mutations Are Common Somatic Events in Melanocytic Nevi 1
Journal of Investigative Dermatology Original Article
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Oncogene Original Article
Journal of Cerebral Blood Flow & Metabolism Original Article
